Trial Profile

Single-arm, Open-label, Safety and Efficacy Study of Radioembolization with Yttrium-90 Microspheres in Combination with Durvalumab (MEDI4736) in Locally Advanced and Unresectable Hepatocellular Carcinoma [HCC]) (SOLID)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jul 2023 Results evaluating preliminary efficacy and safety of combination of radioembolization with yttrium-90 microspheres (Y90-radioembolization) and durvalumab, published in the Clinical Cancer Research
14 Mar 2023 Status changed from active, no longer recruiting to completed.
08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com